Search Within

Sergio Andres Giralt

  1. "Saad Usmani"
Formats
  1. Meeting Abstract (74)
  2. Journal Article (20)
  3. Research Letter (4)
  4. Correspondence (2)
Groups
  1. Bone Marrow Transplant (100)
  2. Center for Hematologic Malignancies (100)
  3. Department of Medicine (100)
  4. Hematologic Malignancies, Division of (100)
  5. Survivorship Research (99)
  6. Myeloma (98)

More Groups

People
  1. Saad Usmani (100)
  2. Sham Mailankody (97)
  3. Gunjan Shah (95)
  4. Alexander Lesokhin (94)
  5. Carlyn Rose Tan (92)
  6. Heather Landau (92)

More People

Years
  1. 2025 (9)
  2. 2024 (36)
  3. 2023 (35)
  4. 2022 (20)
Publications
  1. Blood (39)
  2. Clinical Lymphoma, Myeloma and Leukemia (29)
  3. Journal of Clinical Oncology (8)
  4. Blood Cancer Journal (7)
  5. Blood Advances (6)
  6. New England Journal of Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (45)
  2. Elsevier Inc. (31)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. Massachusetts Medical Society (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (100)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
    Journal Article

    Einarsdottir, S.; Lobaugh, S.; Luan, D.; Gomez-Llobell, M.; Subramanian, P.; Devlin, S.; Chung, D.; Dahi, P. B.; Falchi, L.; Giralt, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save